Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03570918 · ClinicalTrials.gov registry record · Phase 1
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
A Phase 1 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03570918 is a Phase 1 study that has completed, run by MacroGenics. The registered enrollment target is 21 participants.
The verdict
NCT03570918, a Phase 1 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).
Interventions
- BIOLOGICAL MGD014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2021-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03570918
The ClinicalTrials.gov registry entry for NCT03570918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGD014 is the first listed.
NCT03570918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03570918 about?
NCT03570918 is a clinical study titled "MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy". This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).
What is the current status of trial NCT03570918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-09-25. Estimated completion is 2021-09-28.
What interventions are being tested in trial NCT03570918?
The interventions under investigation include: MGD014 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03570918?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.